scholarly journals RELATIONSHIP BETWEEN OBESITY, PSA, AND PROSTATE VOLUME IN PATIENTS WITH BPH WITHOUT URINARY RETENTION

2011 ◽  
Vol 18 (1) ◽  
Author(s):  
Yudi Y Ambeng ◽  
Sabilal Alif ◽  
Doddy M Soebadi
Keyword(s):  
Urinary Retention ◽  
Significant Relationship ◽  
Benign Prostate Hyperplasia ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Significant Negative Correlation ◽  
Obese Patients ◽  
Prostate Hyperplasia ◽  
The Relationship ◽  
Benign Prostate

Objective: To study the relationship between obesity, prostate specific antigen (PSA) level, and prostate volume in patients with benign prostate hyperplasia (BPH) without urinary retention.Material & Method: Twenty two BPH patients without urinary retention were enrolled in this study. Patients were classified into 2 groups based on body mass index (BMI). The first group consisted of 11 patients with obesity (BMI ≥ 27 kg/m2), the second group consisted of 11 non obese patients (BMI <  27 kg/m2). Each patient underwent measurement of PSA, prostate  volume and hematocrit. We performed tests for correlation between all variables in both groups. Results: From correlation testing there was a significant relationship between obesity and PSA. With increasing BMI, a lower PSA level was observed (p< 0,05). There was no significant relationship between prostate volume and hematocrit (p > 0,05).Conclusion: There is a significant negative correlation between obesity and PSA in BPH patients without urinary retention

scholarly journals THE CORRELATIONS AMONG COMPONENTS OF METABOLIC SYNDROME PSA AND PROSTATE VOLUME IN BPH PATIENTS

2016 ◽  
Vol 23 (2) ◽  
Author(s):  
Yanuar Wicaksana Sumasta ◽  
Danarto Danarto
Keyword(s):  
Metabolic Syndrome ◽  
Blood Glucose ◽  
Benign Prostate Hyperplasia ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Adult Treatment Panel ◽  
Prostate Hyperplasia ◽  
Transabdominal Ultrasonography ◽  
Benign Prostate ◽  
Total P

Objective: This study was to evaluate the associations among metabolic components, prostate specific antigen (PSA), and prostate volume (PV) in benign prostate hyperplasia (BPH) patients.Material & method: During the period from January 1, 2010 to August 31, 2013, 61 mens were diagnosed with BPH were enrolled. PV by transabdominal ultrasonography of the prostate, serum PSA, metabolic syndrome (MS) related parameters were investigated. MS was defined according to the modified National Cholesterol Education Program Third Adult Treatment Panel Guidelines. We evaluated the correlation between PSA, PV and MS components using Spearman’s test and Independent t test.Results: PV were not correlated with MS criteria (p=0.591) PSA total also were not correlated with MS criteria (p=0.305). PV were not correlated with each components MS; cholesterol total (p=0.593), trigliserid (p=0.479), HDL (p=0.702), LDL (p=0.512), blood glucose (p=0.317). PSA total were not correlated with each components MS; cholesterol total (p=0.255), trigliserid (p=0.543), HDL (p=0.446), LDL (p=0.615), blood glucose (p=0.987). Conclusion: There were no associations among metabolic syndrome criteria and each components, prostate volume and PSA total.

scholarly journals Study on Estimation of Serum Prostate Specific Antigen Level and Prostate Volume with Trans-Abdominal Ultrasonography Finding in Benign Prostate Hypertrophy at Tertiary Care Hospital : A Cross Sectional Descriptive Study

2021 ◽  
Vol 6 (2) ◽  
pp. 1556-1560
Author(s):  
Chandra Prakash Gaire
Keyword(s):  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Prostate Specific Antigen Level ◽  
Age Group ◽  
Antigen Level ◽  
Prostate Hyperplasia ◽  
Benign Prostate

Introduction: The periurethral and transition zones of the prostatic gland develop benign prostatic hyperplasia and represent an inevitable phenomenon for the ageing male population. Prostatic specific antigen, is a serine protease, level rises in the blood if the barrier between thelining epithelium and the blood stream is damaged. Benign prostatic hyperplasia, prostatic carcinoma and prostatitis are three common diseases where PSA in the serum is raised. Prostate volume also increases according to age, which can be estimated by trans-abdominal ultrasonography. Objective: The aim of the study is to estimate the PSA level in blood and its relationship with prostate volume in benign prostatic hyperplasia patients. Methodology: It is a descriptive cross-sectional study which was carried out between a periods of 1st April 2018 to 31st March 2019 at Birat Medical College Teaching Hospital. All the patients diagnosed with benign prostate hyperplasia at the department of urology were included in the study. Blood samples of patients were analyzed for Prostate specific antigen level estimation by chemiluminescence immunosorbent assay. Prostatic volume of the patients was measured by Transabdominal ultrasound technique. Data were entered and analyzed in Microsoft Excel. Results: A total of 68 patients were diagnosed with benign prostate hyperplasia. The mean age of the patients was 61.8±12.3 years. The maximum number 23 of patients with BPH was there in age group 51-60. The maximum no of patients 38 were having their PSA level between the range of 4.0-10.0 ng/ml. The maximum no of patients 28 was having Prostate volume in the range of 40-60 gm. The maximum number of patients 31 was having diabetes mellitus as a co-morbid association. The maximum mean PSA level and prostate volume in the patients were observed in age group >80 years,which was 20.1±8.6 ng/ml and >80 gm respectively. Conclusion: The prostate specific antigen level and prostate volume both increase in advance age group of patients suffering with benign prostate hyperplasia.

scholarly journals Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Chun-Jen Hsiao ◽  
Tzong-Shin Tzai ◽  
Chein-Hung Chen ◽  
Wen-Horng Yang ◽  
Chung-Hsuan Chen
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Clinical Sample ◽  
Specific Antigen ◽  
Ion Accumulation ◽  
Detection Sensitivity ◽  
Prostate Hyperplasia ◽  
Liquid Chromatography Tandem Mass ◽  
Benign Prostate

Glycans of prostate-specific antigen (PSA) in prostate cancer were found to be different from that in benign disease. It is difficult to analyze heterogeneous PSA glycoforms in each individual specimen because of low protein abundance and the limitation of detection sensitivity. We developed a method for prostate cancer diagnosis based on PSA glycoforms. Specific glycoforms were screened in each clinical sample based on liquid chromatography-tandem mass spectrometry with ion accumulation. To look for potential biomarkers, normalized abundance of each glycoform in benign prostate hyperplasia (BPH) and in prostate cancer was evaluated. The PSA glycoform, Hex5HexNAc4NeuAc1dHex1, and monosialylated, sialylated, and unfucosylated glycoforms differed significantly between the prostate cancer and BPH samples. The detection sensitivity (87.5%) and specificity (60%) for prostate cancer identification are higher than those of the serum PSA marker. As low as 100 amol PSA could be detected with the ion accumulation method which has not been reported before. The improved detection specificity can help reduce unnecessary examinations.

Sign in / Sign up

Export Citation Format

Share Document